Cosdosiran
Based on 1 publication(s) in Google Scholar
Cosdosiran is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.48%
- CAS No.: 1834560-88-1
- Masse moléculaire:12388.68
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
Description
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1834560-88-1
-
Appearance Solid
-
Masse moléculaire 12388.68
-
Color White to off-white
-
SMILES
[Cosdosiran]
-
Synonyms
QPI-1007
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Vis Exp
Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation. [Abstract]2025 Jun 17:(220). PMID: 40622958
Pureté et documentation
Références
[1]. Solano EC, Kornbrust DJ, Beaudry A, Foy JW, Schneider DJ, Thompson JD. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014;24(4):258-266. doi:10.1089/nat.2014.0489 [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)